BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han MAT, Vipani A, Noureddin N, Ramirez K, Gornbein J, Saouaf R, Baniesh N, Cummings-John O, Okubote T, Setiawan VW, Rotman Y, Loomba R, Alkhouri N, Noureddin M. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. Liver Int 2020;40:2242-51. [PMID: 32652744 DOI: 10.1111/liv.14593] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab 2021;50:101167. [PMID: 33460786 DOI: 10.1016/j.molmet.2021.101167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
2 Davis TME. Diabetes and metabolic dysfunction-associated fatty liver disease. Metabolism 2021;123:154868. [PMID: 34400217 DOI: 10.1016/j.metabol.2021.154868] [Reference Citation Analysis]
3 Ozturk A, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY) 2021. [PMID: 34687329 DOI: 10.1007/s00261-021-03269-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yang JY, Qiu BS. The Advance of Magnetic Resonance Elastography in Tumor Diagnosis. Front Oncol 2021;11:722703. [PMID: 34532290 DOI: 10.3389/fonc.2021.722703] [Reference Citation Analysis]
5 Grąt K, Grąt M, Rowiński O. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2020;8:E298. [PMID: 32839409 DOI: 10.3390/biomedicines8090298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Natarajan Y, Loomba R. Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. Journal of Clinical and Experimental Hepatology 2022;12:174-9. [DOI: 10.1016/j.jceh.2021.08.002] [Reference Citation Analysis]
7 Ampuero J. General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. Clin Drug Investig 2022. [PMID: 35467297 DOI: 10.1007/s40261-022-01142-w] [Reference Citation Analysis]
8 Roh YH, Kang BK, Jun DW, Lee CM, Kim M. Role of FIB-4 for reassessment of hepatic fibrosis burden in referral center. Sci Rep 2021;11:13616. [PMID: 34193951 DOI: 10.1038/s41598-021-93038-6] [Reference Citation Analysis]
9 Han MAT. Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. Life (Basel) 2020;10:E198. [PMID: 32933184 DOI: 10.3390/life10090198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Enomoto N, Izumi N. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther 2021. [PMID: 34927277 DOI: 10.1111/apt.16745] [Reference Citation Analysis]
11 Pepin KM, Welle CL, Guglielmo FF, Dillman JR, Venkatesh SK. Magnetic resonance elastography of the liver: everything you need to know to get started. Abdom Radiol (NY) 2021. [PMID: 34725719 DOI: 10.1007/s00261-021-03324-0] [Reference Citation Analysis]
12 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Reference Citation Analysis]
13 Aggarwal P, Noureddin M, Harrison S, Jeannin S, Alkhouri N. Nonalcoholic steatohepatitis (NASH) cirrhosis: A snapshot of therapeutic agents in clinical development and the optimal design for clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032640] [Reference Citation Analysis]
14 Ajmera V, Liu A, Bettencourt R, Dhar D, Richards L, Loomba R. The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography. Aliment Pharmacol Ther 2021;54:68-77. [PMID: 33975381 DOI: 10.1111/apt.16392] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2022;15:175628482210938. [DOI: 10.1177/17562848221093869] [Reference Citation Analysis]